Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

Xavier B. Pivot, Rubi K. Li, Eva S. Thomas, Hyun Cheol Chung, Luis E. Fein, Valorie F. Chan, Jacek Jassem, Fernando Hurtado de Mendoza, Pralay Mukhopadyay, Henri H. Roché

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.

Original languageEnglish
Pages (from-to)2940-2946
Number of pages7
JournalEuropean Journal of Cancer
Volume45
Issue number17
DOIs
Publication statusPublished - 2009 Nov

Bibliographical note

Funding Information:
The authors take full responsibility for the content of this publication and confirm that it reflects their viewpoint and medical expertise. They also wish to acknowledge IneXel and StemScientific, funded by Bristol-Myers Squibb, for providing writing and editing support. Bristol-Myers Squibb did not influence the content of the manuscript, nor did the authors receive financial compensation for authoring the manuscript.

Funding Information:
Xavier Pivot received a commercial research grant from Roche and speakers bureau honoraria from Roche and GlaxoSmithKline. He also served as a consultant on advisory boards for Bristol-Myers Squibb and Cephalon. Jacek Jassem and Henri Roché served as consultants on advisory boards for Bristol-Myers Squibb. Pralay Mukhopadyay is an employee of Bristol-Myers Squibb Company, Inc.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer'. Together they form a unique fingerprint.

Cite this